Recent developments in carbapenems

Bibliography

• KAHAN JS, KAHAN FM, GOEGELMAN R et al.: Thienamycin, a new I3-lactam antibiotic: I. Discovery, taxonomy, isolation and physical properties. Antibiot. (1979) 32:1–12.
   Google Scholar
• KAHAN FM, KROPP H, SUNDELOF JG et al.: Thienamycin: development of imipenem-cilastatin. Antimicrob. Chernother. (1983) 12 (Suppl. D):1–35.
   Google Scholar
• ALBERS-SCHONBERG G, ARISON BH, HENSENS DD et al.: Structure and absolute configuration of thienamycin.j. Arneric. Chelan& Soc. (1978) 100:6491–6499.
   Web of Science ®Google Scholar
• •BASKER MJ: The carbapenem family. Antimicrob. Chernother. (1982) 10:4–7.
   Google Scholar
• HOOD JD, BOX SJ, VERALL MS: Olivanic acids, a family of I3-lactam antibiotics with I3-lactamase inhibitory properties produced by Streptomyces sp. II. Isolation and characterisation of MM 4550, MM 17880.1 Antibiot. (1979) 32:295–304.
   Google Scholar
• BASKER MJ, BOON RJ, HUNTER PA: Comparative antibacterial properties in vitro of seven olivanic acid derivatives-MM 4550, MM 13902, MM17880, MM 22380, MM 22381, MM 22382 and MM 22383.1 Antibiot. (1980) 33:878–884.
   PubMed Web of Science ®Google Scholar
• TSUJI N, KONDO E, MAYAMA M et al.: Asparenomycin A, a new carbapenem antibiotic. Antibiot. (1981) 34:909–911.
   Google Scholar
• TSUJI N, NAGASHIMA K, KOBAYASHI M, TERUI Y, MATSUMOTO K, KONDO E: The structure of pluracidomycins, new carbapenem antibiotics. Antibiot. (1982) 3:536–540.
   Google Scholar
• ITO T, EZAKI N, OHBA K et al.: A novelP-lactamase inhibitor, SF-2103A, produced by a Streptornyces. Antibiot. (1982) 35:533–535.
   Google Scholar
• YAMAGUCHI A, HIRATA T, SAWAI T: Novel carbapenem derivative 5F2103A: studies on the mode of I3-lactamase inactivation. Antimicrob. Agents Chernother (1984) 25.348–353.
   PubMed Web of Science ®Google Scholar
• NAKAYAMA M, IWASAKI A, KIMURA S et al.: Carpetimycin A e B, new P-lactam antibiotics. Antibiot. (1980) 32:1388–1390.
   Google Scholar
• SHIBAMOTO N, KOKI A, NISHINO M et al.: PS-6 and PS-7, new P-lactam antibiotics. Isolation physiochemical properties and structures. Antibiot. (1980) 33:1128–1137.
   Google Scholar
• SHIBAMOTO N, NISHINO M, OKAMURA K, FUGAGAWA Y, ISHIKARA T: PS-8, a minor carbapenem antibiotic. Antibiot. (1982) 35:763–765.
   Google Scholar
• PARKER WL, RATHNUM ML, WELL JS, TREJO WH, PRINCIPE PA, SYKES RB: SQ 27860, a simple carbapenem produced by species of Serratia and Erwiriia.J Antibiot. (1982) 35:563–660.
   Web of Science ®Google Scholar
• ••WISE R: In vitro and pharmacolkinetic properties of the carbapenems. Antimicrob. Agents Chemother. (1986) 30:343–349.
   Google Scholar
• KROPP H, SUNDELOFF JG, KAHAN JS, KAHAN F, BIRNBAUM J: MK0787 (N-formimidoyl thienamycin): evaluation of in vitro and in vivo activities. Antimicrob. Agents Chemother (1980) 17:993–1000.
   PubMed Web of Science ®Google Scholar
• BARZA M: Imipenem: first of a new class of antibiotic. Ann. Inter. Med. (1985) 103:552–560.
   PubMed Web of Science ®Google Scholar
• KROPP H, SUNDELOFF JG, HAJDU R, KAHAN FM: Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase-I. Antimicrob. Agents Chemother. (1982) 22:62–70.
   PubMed Web of Science ®Google Scholar
• •BIRNBAUM J, KAHAN F, KROPP H, MACDONALD JS: Carbapenems, a new class of I3-lactam antibiotics. Discovery and development of imipenem/cilastatin. Am. Medic. (1985) 78:3–21.
   Google Scholar
• •KAHAN F, KROPP M, SUNDELOF JG, BIRNBAUM J: Thienamycin: development of imipenem-cilastatin. Antimicrob. Chemother (1983) 12 (Suppl. D):1–35.
   Google Scholar
• NAGANUMA H, TOKIWA H, HIROUCHI Y et al: Nephroprotective effect and its mechanism of betamipron (2)-Relationships of renal excretion. Chemother (1991) 39\(Suppl. 3):178–189.
   Google Scholar
• TAKAHAGI H, HIROTA T MATSUSHITA Y, MURAMATSU S, TANAKA M, MATSUO E: ha vitro dehydropeptidase-1 activity and its hydrolytic activity of panipenem in several tissue in animal species and their influence on the disposition of panipenem in vivo. Chemother (1991) 39 (Suppl. 3):236–241.
   Google Scholar
• SHIH DH, BAKER F, CAMA L, CHRISTENSEN BG: Synthetic carbapenem antibiotics. I. 1-I3-methylcarbapenem. Heterocycles (1984) 21:29–40.
   Web of Science ®Google Scholar
• FUKASAWA M, SUMITA Y, HARABE ET et al.: Stability of meropenem and effect of 113-methyl substitution on its stability in the presence of renal dehydropeptidase. Antimicrob. Agents Chemother. (1992) 36:1577–1579.
   PubMed Web of Science ®Google Scholar
• EDWARDS JR, TURNER PJ, WANNOP C, WITHNELL ES, GRINDEY AJ, NAIRN K: In vitro antibacterial activity of SM-7338, a carbapenem antibiotic with stability to dehydropeptidase-I. Antimicrob. Agents Chemother (1989) 33:215–222.
   PubMed Web of Science ®Google Scholar
• OGBORNE KT, HITCHCOCK MJM: Radiolabeled quaternary carbapenems and their interactions with human serum albumin. Antimicrob. Agents Chemother (1988) 32:186–189.
   PubMed Web of Science ®Google Scholar
• HIKIDA M, KAWASHIMA K, YOSHIDA M, MITSUHASHI S: Inactivation of new carbapenem antibiotics by dehydropeptidase- I from porcine and human renal cortex. Antimicrob. Chemother. (1992) 30:129–134.
   Web of Science ®Google Scholar
• PETERSEN PJ, JACOBUS NV, WEISS WJ,TESTA RT: In vitro and in vivo activities of LJC10,627, a new carbapenem with stability to dehydropeptidase I. Antimicrob. Agents Chemother (1991) 35:203–207.
   PubMed Web of Science ®Google Scholar
• HIKIDA M, KAWASHIMA K, NISHIKI K et al: Renal dehydropeptidase-I stability of LJC-10,627, a new carbapenem antibiotic. Antimicrob. Agents Chemother. (1992) 36:481–483.
   PubMed Web of Science ®Google Scholar
• GILL CJ, JACKSON JJ, GERCKENS LS et al: In vitro activity and pharmacolkinetic evaluation of a novel long acting carbapenem antibiotic, MK-826 (L-748,345). Antimicrob. Agents Chemother (1998) 42:1996–2001.
   PubMed Web of Science ®Google Scholar
• NAKAGAWA S, HASHIZUME T, MATSUDA K et al.: In vitro activity of a new carbapenem antibiotic, B02727, with potent antipseudomonal activity. Antimicrob. Agents Chemother (1993) 37:2756–2759.
   PubMed Web of Science ®Google Scholar
• ISO Y, IRIE T, NISHINO Y, MOTOKAWA K, NISHITANI Y: A novel 113-methylcarbapenem antibiotic, S-4661: synthesis and structure-activity relationships of 2-(5-substituted pyrrolidin-3-ylthio)-1B-methylcarbapenems. Antibiot. (1996) 49:199–209.
   Google Scholar
• KESSLER RE, FUNG-TOMC J, KOLEK B et al: In vitro activity of BMS-181139, a new carbapenem with potent antipseudomonal activity. Antimicrob. Agents Chemother. (1995) 39:380–385.
   PubMed Web of Science ®Google Scholar
• FUKUOKA T, OHYA S, UTSUI Y et al: In vitro and in vivo antibacterial activities of CS-834, a new oral carbapenem. Antimicrob. Agents Chemother. (1997) 41:2652–2663.
   PubMed Web of Science ®Google Scholar
• DI MODIGANO E, ERBETTI I, FERRARI L, GALASSI G, HAMMOND D, XERRI L: In vitro activity of the tribactam GV104326 against Gram-positive, Gram-negative and anaerobic bacteria. Antimicrob. Agents Chemother(1994) 38:2362–2368.
   PubMed Web of Science ®Google Scholar
• NISHI T, ISHIDA Y, SUGITA K et al.: DZ-2660, a new oral carbapenem antibiotic, 1 :structure activity relationships and M vitro activity. In: Program and Abstracts of the Thirty-Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy Abstract F133. American Society for Microbiology, Washington, DC, USA (1995).
   Google Scholar
• SPRATT BG, TOBANPUTRA V, ZIMMERMANN W: Binding of thienamycin and clavulanic acid to the penicillin-binding proteins of Escherichia cob K-12. Antimicrob. Agents Chemother. (1977) 12:406–409.
   PubMed Web of Science ®Google Scholar
• •SPRATT BG: Properties of penicillin-binding proteins of Escherichia cob K-12. Europ. Biochem. (1977) 72:341–352.
   Google Scholar
• SPRATT BG: Escherichia coliresistance to 13-lactam antibiotics through a decresed in the affinity of a target for lethality. Nature (1978) 274:713–715.
   PubMed Web of Science ®Google Scholar
• YANG Y, BHACHECH N, BUSH K: Biochemical comparison of imipenem, meropenem and biapenem: permeability, binding to penicillin-binding proteins and stability to hydrolysis by I3-lactamases. Antimicrob. Chemother. (1995) 35:75–84.
   Web of Science ®Google Scholar
• SUMITA Y, FUKOSAWA M, OKUDA T: Comparison of two carbapenems, SM-7338 and imipenem: affinities for penicillin-binding proteins and morphological changes. Antibiot. (1990) 43:314–320.
   Google Scholar
• KATO Y, OTSUKI M, NISHINO T: Antibacterial properties of BO-2727, a new carbapenem antibiotic. j. Antimicrob. Chemother. (1997) 40:195–203.
   PubMed Web of Science ®Google Scholar
• FUNG-TOMC JC, GRADELSKI E, KOLEK B et al.: Activity of carbapenem BMS-181139 against Pseudomonas aemginosa is not dependent on porin protein D2. Antimicrob. Agents Chemother. (1995) 39:386–393.
   PubMed Web of Science ®Google Scholar
• SUMITA Y, FUKOSAWA M, OKUDA T: Affinities of SM-7338 for penicillin-binding proteins and its release from these proteins in Staphylococcus moms. Antimicrob. Agents Chemother. (1990) 34:484–486.
   PubMed Web of Science ®Google Scholar
• MURAKAMI K, DOI M, YOSHIDA T: Asparenomycins A, B and C, new carbapenems antibiotics. V. Inhibition of 13-lactamases. Antibiot. (1982) 35:39–45.
   Google Scholar
• CHARMAS RL, KNOWELS JR: Inhibition of RTEM I3-lactamase from Escherichia cob. Interactions with derivatives of olivanic acids. Biochemistry (1981) 20:2732–2737.
   Google Scholar
• KOBAYASHI F, SAINO Y, KOSHI T et al: Antimicrobial and I3-lactamases activities of carpetimycins A and B, new carbapenem antibiotics. Antimicrob. Agents Chemother. (1982) 21:536–544.
   PubMed Web of Science ®Google Scholar
• OKONOGI K, NOZAKI Y, IMADA A, KUNG M: C-19393 S2 and H2, new carbapenem antibiotics. IV. Inhibitory activity against I3-lactamases. Antibiot. (1981) 34: 212–217.
   Google Scholar
• OKAMURA K, SAKAMOTO M, ISHIKURA T: PS-5 inhibition of a p-lactamase from Proteus vulgaris Antibiot. (1980) 33:293-302.
   Google Scholar
• RICHMOND MH: The semi-synthetic thienamicin derivative MK-0787 and its properties with respect to a range ofl3-lactamases from clinically important bacterial species. Antimicrob. Cheinother. (1981) 7:279–285.
   PubMed Web of Science ®Google Scholar
• SAWAI T, TSUKAMOTO K: Cefoxitin, N-formimidoyl thienamycin, clavulanic acid and penicillanic sulfone as suicide inhibitors for different types of I3-lactamases produced by Gram-negative bacteria.' Antibiot. (1982) 35:1594–1602.
   Google Scholar
• MONKS J, WALEY SG: Imipenem as substrate and inhibitor of I3-lactamases. Biochein. (1988) 253:323–328.
   PubMed Web of Science ®Google Scholar
• LABIA R, MORAND A, GUIONIE M: Beta-lactamase stability of imipenem. .1 Antimicrob. Cheinother. (1986) 18(Suppl. E):1–8.
   Google Scholar
• LABIA R, MORAND A, TIWARI K, SIROT D, CHANAL C: Interactions of meropenem, with I3-lactamases, including enzymes with extended spectrum activity against third generation cephalosporins. Antimicrob. Cheinother. (1989) 24(Suppl.A):219–223.
   Google Scholar
• •SANDERS CC, SANDERS Jr WE, THOMSON KS, IACONIS JP: Meropenem: activity against resistant Gram-negative bacteria and interactions with 13-lactamases. Antimicrob. Cheinother (1989) 24(Suppl.A):187–196.
   Google Scholar
• •FELICI A, PERILLI M, SEGATORE B et al.: Interactions of biapenem with active-site serine and metallo-I3-lactamases. Antimicrob. Agents Cheinother (1995) 39:1300–1305.
   PubMed Web of Science ®Google Scholar
• BUSH K, JACOBY GA, MEDEIROS AA: A functional classification scheme for 13-lactamases and its correlation with molecular structure. Antimicrob. Agents Cheinother. (1995) 39:1211–1233.
   PubMed Web of Science ®Google Scholar
• •FRERE JM: Beta-lactamases and bacterial resistance to antibiotics. Mol. Microbiol (1995) 16:385–395.
   Google Scholar
• •BUSH, K: Metallo-I3-lactamases: a class apart. Clin. Infect. Dis. (1998) 27:S48–S53.
   PubMed Web of Science ®Google Scholar
• ••LIVERMORE DM: I3-Lactamases in laboratory and clinical resistance. Clin. Microbiol. Rey (1995) 8:557–584.
   PubMed Web of Science ®Google Scholar
• ”RASSMUSSEN BA, BUSH K: Carbapenem-hydrolyzing I3-lactamases. Antimicrob. Agents Cheinother (1997). 41:223–232.
   PubMed Web of Science ®Google Scholar
• ••AMBLER RP: The structure ofl3-lactamases. Philos. Trans. R. Soc. Lond. B. Biol. Sci (1980) 289:321–331.
   PubMed Web of Science ®Google Scholar
• BUSH K, TANAKA SK, BONNER DP, SYKES RB: Resistance caused by decreased penetration ofl3-lactam antibiotics into Enterobacter cloacae. Antimicrob. Agents Cheinother. (1985) 27:555–560.
   PubMed Web of Science ®Google Scholar
• BOU G, OLIVER A, MARTINEZ-BELTRAN J: OXA-24, a novel class D beta-lactamase with carbapenemase activity in an Acinetobacter baumannii clinical strain. Antimicrob. Agents Cheinother. (2000) 44:1556–1561.
   PubMed Web of Science ®Google Scholar
• •LIVERMORE DM: Carbapenemases. Antimicrob. Cheinother (1992) 29:609–616.
   Google Scholar
• •FELICI A, AMICOSANTE A, ORATORE R et al.: An overview of the kinetic parameters of class B I3-lactamases. Biochein. J. (1993) 291:151–155.
   PubMed Web of Science ®Google Scholar
• SAINO Y, KOBAYASHI F, INOUE M, MITSUASHI S: Purification and properties of inducible penicillin I3-lactamase isolated from Pseudomonas inaltophilia. Antimicrob. Agents Cheinother. (1982) 22:564–570.
   PubMed Web of Science ®Google Scholar
• BICKNELL R, EMANUEL EL, GAGNON J, WALEY SG: The production and molecular properties of the zinc I3-lactamase from Pseudomonas inaltophilia IID 1275. Biochein. J. (1985) 229:791–797.
   PubMed Web of Science ®Google Scholar
• IACONIS JP, SANDERS CC: Purification and characterization of induciblel3-lactamases in Aeromonasspp. Arkin-du-ob. Agents Cheinother. (1990) 34:44–51.
   PubMed Web of Science ®Google Scholar
• FUJII T, SATO K, MIYATA K, INOUE M MITSUASHI S: Biochemical properties ofl3-lactamase produced by Legionella gormanii Antimicrob. Agents Cheinother. (1986) 29:925–926.
   PubMed Web of Science ®Google Scholar
• SATO K, FUJII R, OKATOMO R, INOUE M, MITSUASHI S: Biochemical properties of P-lactamases produced by Flavobacterium odoratum. Antimicrob. Agents Cheinother (1985) 27:612–614.
   PubMed Web of Science ®Google Scholar
• BELLAIS S, LEOTARD S, POIREL L, NAAS T, NORDMANN P: Molecular characterization of a carbapenem-hydrolyzing beta-lactamase from Cloyseobacterium (Davobacterium) indologenes. FEMS Microbiol. Lett. (1999) 171:127–132.
   PubMed Web of Science ®Google Scholar
• BELLAIS S, AUBERT D, NAAS T, NORDMANN P: Molecular and biochemical heterogeneity of class B carbapenem-hydrolyzing p-lactamases in Cloyseobacterium meningosepticum. Antimicrob. Agents Cheinother. (2000) 44:1878–1886.
   PubMed Web of Science ®Google Scholar
• CUCHURAL GJ, MALAMY MH, TALLY FP: P-Lactamase-mediated imipenem resistance in Bacteroides fragilis. Antimicrob. Agents Cheinother. (1986) 30:645–648.
   PubMed Web of Science ®Google Scholar
• ROSSOLINI GM, CONDEMI MA, PANTANELLA F, DOCQUIER JD, AMICOSANTE G, THALLER MC: Metallo-P-Lactamase Producers in Environmental Microbiota: New Molecular Class B Enzyme in Janthinobacterium lividum. Antimicrob. Agents Cheinother. (2001) 45:837–844.
   PubMed Web of Science ®Google Scholar
• •WATANABE M, IYOBE S, INOUE M, MITSUASHI S: Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob. Agents Cheinother. (1991) 25:891–902.
   Google Scholar
• CORNAGLIA G, RICCIO ML, MAZZARIOL A, LAURETTI L, FONTANA R, ROSSOLINI G: Appearance of IMP-1 metallo-beta-lactamase in Europe. Lancet (1999) 353:899–900.
   PubMed Web of Science ®Google Scholar
• LAURETTI L, RICCIO ML, MAZZARIOL A et aL: Cloning and characterization of b/avim, a new integron-borne metallo-P-lactamase gene from a Pseudomonas aeruginosa clinical isolate. Antimicrob. Agents Cheinother. (1999) 43:1584–1590.
   PubMed Web of Science ®Google Scholar
• POIREL L, NAAS T, NICHOLAS D et al:Characterization of VIM-2, a carbapenem-hydrolyzing metallo-P-lactamase and its plasmid- and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France. Antimicrob. Agents Cheinother (2000) 44:891–897.
   PubMed Web of Science ®Google Scholar
• PALLECCHI L, RICCIO ML, DOCQUIER JD, FONTANA R, ROSSOLINI GM: Molecular heterogeneity of bla(VIM-2)-containing integrons from Pseudomonas aeruginosa plasmids encoding the VIM-2 metallo-beta-lactamase. FEMS Microbiol. Lett. (2001) 195:145–50.
   PubMed Web of Science ®Google Scholar
• OSANO E, ARAKAWA Y, WACHAROTAYANKUN R et al.: Molecular characterization of an enterobacterial metallo-P-lactamase found in a clinical isolate of Serratia mairescens that shows imipenem resistance. Arkin-du-ob. Agents Cheinother (1994) 38:71–78.
   PubMed Web of Science ®Google Scholar
• KOH TH, BABINI G, WOODFORD N, SNG LH, HALL LM, LIVERMORE DM: Carbapenem-hydrolyzing IMP-1 P-lactamase in Klebsiella pneumoniae from Singapore. Lancet (1999) 353:819.
   Web of Science ®Google Scholar
• RICCIO ML, FRANCESCHINI N, BOSCHI L et al.: Characterization of the metallo-I3-lactamase determinant of Acinetobacter baumanni AC-54I97 reveals the existence of b/a(IMP) allele variants carried by gene cassettes of different phylogeny. Antimicrob. Agents Chemother (2000) 44:1229–1235.
   PubMed Web of Science ®Google Scholar
• YGIT H, QUEENAM AM, ANDERSON GJ et al: Novel carbapenem-hydrolyzing 13-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob. Agents Chemother: (2001) 45:1151–1161.
   Google Scholar
• GALLENI M, LAMOTTE-BRASSEUR J, ROSSOLINI GM, SPENCER J, DIDEBERG 0, FRERE JM, AND THE METALLO-B-LACTAMASE WORKING GROUP: Standard numbering scheme for Class B P-lactamases. (2001) Antimicrob. Agents Chemother 45:660–663.
   Web of Science ®Google Scholar
• ITO H, ARAKAWA Y, OHSUKA S, WACHARATAYANKUN R, KATO N, OHTA M: Plasmid-mediated dissemination of the metallo-I3-lactamase gene blaIMP among clinically isolated strains of Serratia marcescens. Antimicrob. Agents Chemother. (1995) 39:824–829.
   PubMed Web of Science ®Google Scholar
• QUINN JP, STUDEMEINSTER AE, DIVINCENZO CA, LERNER SA: Resistance to imipenem in Pseudomonas aeruginosa: clinical observations and biochemical mechanism. Rev Infect. Dis. (1988) 10:892–898.
   PubMedGoogle Scholar
• •TRIAS J, DUFRESNE J, LEVESQUE RC, NIKAIDO H: Decreased outer membrane permeability in imipenem-resistant mutants in Pseudomonas aeruginosa. Antimicrob. Agents Chemother (1989) 33:1201–1206.
   Google Scholar
• •TRIAS J, NIKAIDO H: Outer membrane protein D2 channel catalyses facilitated diffusion of carbapenems and penems through the outer membrane of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. (1990) 34:52–57.
   PubMed Web of Science ®Google Scholar
• SATAKE S, YONEYAMA H, NAKAE T: Role of OmpD2 and chromosomal 13-lactamase in carbapenem resistance in clinical isolates of Pseudomonas aeruginosa. .1 Antimicrob. Chemother. (1991) 32:199–207.
   Web of Science ®Google Scholar
• TRIAS J, NIKAIDO H: Protein D2 channel of the Pseudomonas aeruginosa outer membrane has a binding site for basic amino acids and peptides. Biol. Chem. (1990) 265:15680–15684.
   Web of Science ®Google Scholar
• SUMITA Y, FUKASAWA M: Meropenem resistance in Pseudomonas aeruginosa. Chemother (1996) 42:47–56.
   PubMed Web of Science ®Google Scholar
• BONFIGLIO G, MACCARONE G, MEZZATESTA ML et al.: In vitro activity of biapenem against recent clinical isolates. Chemother. (1997) 43:393–399.
   PubMed Web of Science ®Google Scholar
• SHIMADA K: Overview of a new carbapenem, panipenem/betamipron. Drugs Exp. Clin. Res. (1994) 20:241–245.
   PubMedGoogle Scholar
• TSUJI M, ISHII Y, OHNO A, MIYAZAKI S, YAMAGUCHI: In vitro and M vivo antibacterial activities of S-4661, a new carbapenem. Antimicrob. Agents Chemother (1998) 42:94–99.
   PubMed Web of Science ®Google Scholar
• LI XZ, ZHANG L, POOLE K: Interplay between the MexA-MexB-OprM multidrug efflux system and the outer membrane barrier in the multiple antibiotic resistance of Pseudomonas aeruginosa. Antimicrob. Chemother (2000) 45:433–436.
   Web of Science ®Google Scholar
• •SRIKUMAR R, PAUL CJ, POOLE K: Influence of mutations in the mexR repressor gene on expression of the MexA-MexB-OprM multidrug efflux system of Pseudomonas aeruginosa. Bacteria (2000) 182: 1410–1414.
   Google Scholar
• MASEDA H, YONEYAMA H, NAKAE T: assignment of the substrate-selective subunits of the MexE-MexF-OprN multidrug efflux pump of Pseudomonas aeruginosa. Antimicrob. Agents Chemother (2000) 44:658–664.
   PubMed Web of Science ®Google Scholar
• KOHLER T, EPP SF, CURTY LK, PECHERE JC: Characterization of the MexT, the regulator of the MexE-MexF-OprN multidrug efflux system of Pseudomonas aeruginosa. Bacteria (1999) 181:6300–6305.
   PubMed Web of Science ®Google Scholar
• MOELLERING Jr RC, ELIOPOULOS GM, SENTOCHNIK ED: The carbapenems: new broad spectrum I3-lactam antibiotics. J. Antimicrob. Chemother. (1989) 24(Suppl.A):1–7.
   Google Scholar
• ALONSO R, FDEZ-ARANGUIZ A, COLOM et al.: In vitro activity of biapenem against beta-lactamase producing Enterobacteriaceae. Ear: Clin. Microbia Infect. Dis. (1994) 13:820–822.
   PubMed Web of Science ®Google Scholar
• ASAHI YA, MIYAZAKI S, YAMAGUCHI K: In vitro and in vivo antibacterial activities of BO-2727, a new carbapenem. Antimicrob. Agents Chemother (1995) 39:1030–1037.
   PubMed Web of Science ®Google Scholar
• LIVERMORE DM, YANG Y: Comparative activity of meropenem against Pseudomonas aeruginosa strains with well-characterised resistance mechanisms. Antimicrob. Chemoth. (1989) 24(Suppl. A):149–159
   Google Scholar
• •EDWARDS JR: Meropenem: a microbiological overview. .1 AntimicrobChemother. (1995) 36(Suppl. A):1–17.
   Google Scholar
• PFALLER MA, JONES RN: A review of the M vitro activity of meropenem and comparative antimicrobial agents tested against 30,254 aerobic and anaerobic pathogens isolated worldwide. Diagnost. Microb. Inf. Dis. (1997) 28:157–163.
   PubMed Web of Science ®Google Scholar
• TURNER PJ: MYSTIC (meropenem yearly susceptibility test information collection): a global overview. Antimicrob. Chemother: (2000) 46(topic T2):9–23.
   Google Scholar
• INOUE K, HAMANA Y, MITSUASHI S: In vitro antibacterial activity and P-lactamase stability of a new carbapenem, BO-2727. Antimicrob. Agents Chemother. (1995) 39:2331–2336.
   PubMed Web of Science ®Google Scholar
• •EDWARDS JR, TURNER PJ: Laboratory data which differentiate meropenem and imipenem. Scand.J. Infect. Dis. (1995) 96(Suppl.):5–10.
   Google Scholar
• CHEN HY, YUAN M, IBRAHIM-ELMAGBOUL IB, LIVERMORE DM: National survey of susceptibility to antimicrobials amongst clinical isolates of Pseudomonas aeruginosa. Antimicrob. Chemother. (1995) 35:521–524.
   Web of Science ®Google Scholar
• BONFIGLIO G, CARCIOTTO V, RUSSO G et al.: Antibiotic resistance in Pseudomonas aeruginosa. An Italian survey. Antimicrob. Chemother. (1998) 41:307–310.
   PubMed Web of Science ®Google Scholar
• BONFIGLIO G, LAKSAI Y, FRANCHINO L, AMICOSANTE G, NICOLETTI G: Mechanisms of 13-lactam resistance in Italian isolates of Pseudomonas aeruginosa. Antimicrob. Chemother. (1998) 42:697–702.
   Web of Science ®Google Scholar
• PFALLER MA, JONES RN, FOR THE MYSTIC STUDY GROUP (AMERICAS): MYSTIC (meropenem yearly susceptibility test information collection) results from the Americas: resistance implications in the treatment of serious infections. Antimicrob. Chemother. (2000) 46(Topic T2):25–37.
   Google Scholar
• GOOSSENS H, FOR THE MYSTIC STUDY GROUP (EUROPEAN CENTRES ONLY): MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Europe: comparison of antibiotic susceptibilities between countries and centre types. Antimicrob. Chemother (2000) 46(Topic T2):39–52.
   Google Scholar
• HAZUMI N, FUSE A, MATSUDA K, HASHIZUME T, SANADA M: Mechanism of enhanced antipseudomonal activity of BO-2727, a new injectable 1-I3-methyl carbapenem. Antimicrob. Agents Chemother (1995) 39:702–706.
   PubMed Web of Science ®Google Scholar
• OHBA F, NAKAMURA-KAMIJO M, WATANABE N-A, KATSU: In vitro and in vivo antibacterial activities of ER-35786, a new antipseudomonal carbapenem. Antimicrob. Agents Chemother (1997) 41:298–307.
   PubMed Web of Science ®Google Scholar
• OKUDA J, OTSUKI M, OH T, NISHINO T: hi vitro activity of DU-6681a, an active form of the new oral carbapenem compound DZ-2640, in comparison with that of R-95867, faropenem and oral cephalosporins. Antimicrob. Chemother (2000) 46:101–108.
   Web of Science ®Google Scholar
• KITZIS MD, ACAR JF, GUTMANN L: Antibacterial activity of meropenem against Gram-negative bacteria with a permeability defect and against staphylococci. J. Antimicrob. Chemother (1989) 24\(Suppl. 4125–132.
   Google Scholar
• FISH DN, SINGLETARY TJ: Meropenem a new carbapenem antibiotic. Pharmacotherapy (1997) 17:644–669.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN EJC, CITRON DM, MERRIAM CV, WARREN Y TYRREL KL: Comparative M vitro activities of ertapenem (MK-0826) against 1,001 anaerobes isolated from human intra-abdominal infections. Antimicrob. Agents Chemother (2000) 44:2389–2394.
   PubMed Web of Science ®Google Scholar
• WEXLER KM, MOLITORIS E, FINGOLD SM: The M vitro activity of L-627 against anaerobic bacteria. Antimicrob. Chemother. (1994) 33:629–634.
   Web of Science ®Google Scholar
• KATO N, TANAKA K, KATO H, WATANABE K: in vitroactivity of R-95867, the active metabolite of a new oral carbapenem, CS-834, against anaerobic bacteria. Antimicrob. Chemother. (2000) 45:357–361.
   Web of Science ®Google Scholar
• BETRIUC C, GOMEZM, PALAN ML, SANCHEZ A, PICAZO JJ: Activities of new antimicrobial agents (trovafloxacin, mwdfloxacin, sanfetrinem and quinupristin-dalfopristin) against Bacteroides fragilisgroup: comparison with the activities of 14 other agents. Antimicrob. Agents Chemother (1999) 43:2320–2322.
   PubMed Web of Science ®Google Scholar
• DI MODUGANO E, BROGGIO R, ERBETTI I, LOWTHER J: In vitro and in vivo antibacterial activities of GV129606, a new broad spectrum trinem. Antimicrob. Agents Chemother (1997) 41:2742–2748.
   PubMed Web of Science ®Google Scholar
• COLARDYN F, FAULKNER KL, FOR THE MEROPENEM SERIOUS INFECTION STUDY GROUP: Intravenous meropenem versus imipenem/ cilastatin in the treatment of serious bacterial infections in hospitalised patients. Antimicrob. Chemother (1996) 38:523–537.
   Web of Science ®Google Scholar
• GARAU J, BLANQUER J, COBO Let al.: Prospective, randomised, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections. Ear: I Clin. Microbial. Infect. D (1997) 16:789–796.
   Google Scholar
• MOUTON YJ, BEUSCART C, MEROPENEM STUDY GROUP: Empirical monotherapy with meropenem in serious bacterial infections. J. Antimicrob. Chemother (1995) 36(Suppl. A):145–156.
   Google Scholar
• DIRKSEN MSC, WINTERMANS RFG, BOEREMA JBJ, GIMBRERE JSF: Imipenem as monotherapy in the treatment of intensive care patients with severe infections. Antimicrob. Chemother (1986) 18(Suppl. E):145–151.
   Google Scholar
• HUGHES WT, ARMSTRONG D, BODEY G et al.: Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin. Infect. Dis. (1997) 25:551–557.
   PubMed Web of Science ®Google Scholar
• COMETTA A, GLAUSER MP: Empiric antibiotic monotherapy with carbapenems in febrile neutropenia: a review. J. Chemother. (1996) 8:375–381.
   PubMed Web of Science ®Google Scholar
• LINDBLAD R, RODJER S, ADRIANSSON M et al.: Empiric monotherapy for febrile neutropenia - a randomised study comparing meropenem with ceftazidime. Scand. J. Infect. Dis. (1998) 30: 237–243.
   PubMed Web of Science ®Google Scholar
• BEHRE G, LINK H, MASCHMEYER G et al.: Meropenem monotherapy versus combination therapy with ceftazidime and amikacin for empirical treatment of febrile neutropenic patients. Ann. Hematol (1998) 76:73–80.
   PubMed Web of Science ®Google Scholar
• LAMB HM, GOA KL: Management of febrile episodes in neutropenic patients. Dis. Manage Health Outcomes. (1999) 5:101–116.
   Google Scholar
• HAMACHER J, VOGELL F, LICHEY J et al. Treatment of acute bacterial exacerbations of chronic obstructive pulmonary disease in hospitalised patients, a comparison of meropenem and imipenem/ cilastatin: COPD Study Group. .1 Antimicrob Chemother (1995) 36(Suppl. A):121–133.
   Google Scholar
• AMERICAN THORACIC SOCIETY: Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategy. Am. J. Respir. Grit. Care. (1996) 153:1711–1725.
   PubMed Web of Science ®Google Scholar
• SIEGER B, BERMAN SJ, GECKLER RW, FARKAS SA: Empiric treatment of hospital- acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: a randomised study: Meropenem Lower Respiratory Infection Group. Crit. Care Med (1997) 25:1663–1670.
   PubMed Web of Science ®Google Scholar
• FINCH RG, PENBERTON K, GILDON KM. Pneumonia: the impact of risk factors on the outcome of treatment with meropenem and ceftazidime. j. Chemother. (1998) 10:35–46.
   Google Scholar
• •BRADLEY JS, GARAU J, LODE H, ROLSTON KVI, WILSON SE, QUINN JP: Carbapenems in clinical practice: a guide to their use in serious infection. Intern. J. Antimicrob. Agents. (1999) 11:93–100.
   Google Scholar
• POENARU D, SANTIS M, CHRISTOU NV: Imipenem versus tobramycin-antianaerobe antibiotic therapy in intra-abdominal infections. Can. .1. Sing. (1990) 33:415–422.
   Web of Science ®Google Scholar
• SOLOMKIN JS, DELLINGER EP, CRISTOU NV, BUSUTTIL RVV: Results of a multicenter trial comparing imipenem/ cilastatin to tobramycin/clindamycin for intraabdominal infections. Ann. Surg. (1990) 212:581–591.
   PubMed Web of Science ®Google Scholar
• HESELTINE PNR, YELLIN AE, APPLEMAN MD et al.: Imipenem therapy for perforated and gangrenous appendicitis. Surg. Cynecol Obstet. (1986) 162:43–48.
   PubMedGoogle Scholar
• BRISMAR B, AKERLUND J-E, SJOSTEDT S et al: Biapenem versus imipenem/cilastatin in the treatment of complicated intra-abdominal infections: report from Swedish study group. Scand.J. Infect. Dis (1996) 28:507–512.
   PubMed Web of Science ®Google Scholar
• CONDON RE, WALKER AP, SIRINEK KR et al.: Meropenem versus tobramycin plus clindamycin for treatment of intrabdominal infections: results of a prospective, randomised, double-bind clinical trial. Clin. Infect. Dis (1995) 21: 544–550.
   PubMed Web of Science ®Google Scholar
• •WILSON SE: Meropenem in the treatment of intra-abdominal infection: review of the clinical trials. Adv. Ther: (1997) 14:110–115.
   Google Scholar
• KEMPF P, BAUERNFEIND A, MULLER A, BLUM J: Meropenem monotherapy versus cefotaxime plus metronidazole combination treatment for serious intra-abdominal infections. Infection (1996) 24:473–479.
   PubMed Web of Science ®Google Scholar
• ZANETTI G, HARBARTH SJ, TRAMPUZ A et al.: Meropenem (1.5 g/day) is as effective as imipenem/cilastatin (2 g/day) for the treatment of moderately severe intra- abdominal infections. mt. J. Antimicrob. Agents. (1999) 11:107–113.
   Google Scholar
• KANELLAKOPOULOU K, GIAMMARELLU H, PAPADOTHOMAKOS P et al.: Meropenem versus imipenem/cilastatin in the treatment of intraabdominal infetions requiring surgery. Eat J Clin Microbiol Infect. Dis. (1993) 12:449–453.
   PubMed Web of Science ®Google Scholar
• BRADLEY JS: Selecting therapy for serious infections in children: maximizing safety and efficacy. Diagn. Microb. Infect. Dis. (1998) 31:405–410.
   PubMed Web of Science ®Google Scholar
• KLUGMAN KP, DAGAN RAND THE MEROPENEM MENINGITIS STUDY GROUP: A randomised comparison of meropenem with cefotaxime for the treatment of bacterial meningitis. Antimicrob. Agents Chemother (1995) 39:1140–1146.
   PubMed Web of Science ®Google Scholar
• •EDWARDS JR, BETT MJ: Carbapenems: the pinnacle of the I3-lactam antibiotics or room for improvement?' Antimicrob. Chemother. (2000) 45:1–4.
   Web of Science ®Google Scholar